Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology and Hepatology
Volume 2016, Article ID 6193275, 13 pages
http://dx.doi.org/10.1155/2016/6193275
Research Article

Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding Varies Widely: A Need for Further Education

1Division of Gastroenterology, Faculty of Medicine, University of Alberta, Edmonton, AB, Canada
2Faculty of Nursing, University of Alberta, Edmonton, AB, Canada

Received 16 August 2015; Accepted 25 August 2016

Academic Editor: Geoffrey C. Nguyen

Copyright © 2016 Vivian Wai-Mei Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. W. Ng and U. Mahadevan, “Management of inflammatory bowel disease in pregnancy,” Expert Review of Clinical Immunology, vol. 9, no. 2, pp. 161–174, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Mountifield, P. Bampton, R. Prosser, K. Muller, and J. M. Andrews, “Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions,” Inflammatory Bowel Diseases, vol. 15, no. 5, pp. 720–725, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. R. E. Mountifield, R. Prosser, P. Bampton, K. Muller, and J. M. Andrews, “Pregnancy and IBD treatment: this challenging interplay from a patients' perspective,” Journal of Crohn's and Colitis, vol. 4, no. 2, pp. 176–182, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. C. P. Selinger, J. Eaden, W. Selby et al., “Inflammatory bowel disease and pregnancy: lack of knowledge is associated with negative views,” Journal of Crohn's and Colitis, vol. 7, no. 6, pp. e206–e213, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. Z. Zelinkova, P. B. Mensink, J. Dees, E. J. Kuipers, and C. J. Van Der Woude, “Reproductive wish represents an important factor influencing therapeutic strategy in inflammatory bowel diseases,” Scandinavian Journal of Gastroenterology, vol. 45, no. 1, pp. 46–50, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Blumenstein, E. Herrmann, N. Filmann et al., “Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity. A subgroup analysis of a large multi-centre, prospective, internet-based study,” Journal of Crohn's and Colitis, vol. 5, no. 3, pp. 203–210, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Peyrin-Biroulet, A. Oussalah, X. Roblin, and M. P. Sparrow, “The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts,” Alimentary Pharmacology and Therapeutics, vol. 33, no. 6, pp. 707–713, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J. H. Yeung, K. J. Goodman, and R. N. Fedorak, “Inadequate knowledge of immunization guidelines: a missed opportunity for preventing infection in immunocompromised IBD patients,” Inflammatory Bowel Diseases, vol. 18, no. 1, pp. 34–40, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Tan, R. H. Holloway, K. Lange, and J. M. Andrews, “General practitioners' knowledge of and attitudes to inflammatory bowel disease,” Internal Medicine Journal, vol. 42, no. 7, pp. 801–807, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Toomey and B. Waldron, “Family planning and inflammatory bowel disease: the patient and the practitioner,” Family Practice, vol. 30, no. 1, pp. 64–68, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Bröms, F. Granath, M. Linder, O. Stephansson, M. Elmberg, and H. Kieler, “Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure,” Inflammatory Bowel Diseases, vol. 20, no. 6, pp. 1091–1098, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Pedersen, A. Bortoli, D. Duricova et al., “The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women,” Alimentary Pharmacology and Therapeutics, vol. 38, no. 5, pp. 501–512, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Mogadam, W. O. Dobbins, B. I. Korelitz, and S. W. Ahmed, “Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome,” Gastroenterology, vol. 80, no. 1, pp. 72–76, 1981. View at Google Scholar · View at Scopus
  14. F. M. Habal, G. Hui, and G. R. Greenberg, “Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course,” Gastroenterology, vol. 105, no. 4, pp. 1057–1060, 1993. View at Publisher · View at Google Scholar · View at Scopus
  15. O. Diav-Citrin, Y.-H. Park, G. Veerasuntharam et al., “The safety of mesalamine in human pregnancy: a prospective controlled cohort study,” Gastroenterology, vol. 114, no. 1, pp. 23–28, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Marteau, R. Tennenbaum, E. Elefant, M. Lémann, and J. Cosnes, “Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules,” Alimentary Pharmacology and Therapeutics, vol. 12, no. 11, pp. 1101–1108, 1998. View at Publisher · View at Google Scholar · View at Scopus
  17. D. N. Moskovitz, C. Bodian, M. L. Chapman et al., “The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients,” The American Journal of Gastroenterology, vol. 99, no. 4, pp. 656–661, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Nørgård, L. Pedersen, L. A. Christensen, and H. T. Sørensen, “Therapeutic drug use in women with crohn's disease and birth outcomes: a danish nationwide cohort study,” American Journal of Gastroenterology, vol. 102, no. 7, pp. 1406–1413, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Rahimi, S. Nikfar, A. Rezaie, and M. Abdollahi, “Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis,” Reproductive Toxicology, vol. 25, no. 2, pp. 271–275, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. C. J. van der Woude, S. Ardizzone, M. B. Bengtson et al., “The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease,” Journal of Crohn's and Colitis, vol. 9, no. 2, pp. 107–124, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. O. H. Nielsen, C. Maxwell, and J. Hendel, “IBD medications during pregnancy and lactation,” Nature Reviews Gastroenterology and Hepatology, vol. 11, no. 2, pp. 116–127, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. I. Mylonas, “Antibiotic chemotherapy during pregnancy and lactation period: aspects for consideration,” Archives of Gynecology and Obstetrics, vol. 283, no. 1, pp. 7–18, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Bar-Oz, M. E. Moretti, R. Boskovic, L. O'Brien, and G. Koren, “The safety of quinolones—a meta-analysis of pregnancy outcomes,” European Journal of Obstetrics & Gynecology and Reproductive Biology, vol. 143, no. 2, pp. 75–78, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. D. K. Gardner, S. G. Gabbe, and C. Harter, “Simultaneous concentrations of ciprofloxacin in breast milk and in serum in mother and breast-fed infant,” Clinical Pharmacy, vol. 11, no. 4, pp. 352–354, 1992. View at Google Scholar · View at Scopus
  25. A. Francella, A. Dyan, C. Bodian, P. Rubin, M. Chapman, and D. H. Present, “The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study,” Gastroenterology, vol. 124, no. 1, pp. 9–17, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. V. Langagergaard, L. Pedersen, M. Gislum, B. Nørgard, and H. T. Sørensen, “Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study,” Alimentary Pharmacology and Therapeutics, vol. 25, no. 1, pp. 73–81, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Coelho, L. Beaugerie, J. F. Colombel et al., “Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study,” Gut, vol. 60, no. 2, pp. 198–203, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. O. Stephansson, H. Larsson, L. Pedersen et al., “Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden,” Inflammatory Bowel Diseases, vol. 17, no. 3, pp. 795–801, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. L. Shim, G. D. Eslick, A. A. Simring, H. Murray, and M. D. Weltman, “The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD),” Journal of Crohn's and Colitis, vol. 5, no. 3, pp. 234–238, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. M. J. Casanova, M. Chaparro, E. Domench et al., “Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease,” American Journal of Gastroenterology, vol. 108, no. 3, pp. 433–440, 2013. View at Publisher · View at Google Scholar
  31. M. Akbari, S. Shah, F. S. Velayos, U. Mahadevan, and A. S. Cheifetz, “Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 19, no. 1, pp. 15–22, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. M. E. Lloyd, “The effects of methotrexate on pregnancy, fertility and lactation,” Quarterly Journal of Medicine, vol. 92, pp. 551–563, 1999. View at Publisher · View at Google Scholar
  33. C. O. Drugs, “The transfer of drugs and other chemicals into human milk,” Pediatrics, vol. 108, no. 3, pp. 776–789, 2001. View at Google Scholar
  34. R. Arsenescu, V. Arsenescu, and W. J. S. de Villiers, “TNF-α and the development of the neonatal immune system: implications for inhibitor use in pregnancy,” American Journal of Gastroenterology, vol. 106, no. 4, pp. 559–562, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. U. Mahadevan, S. Kane, W. J. Sandborn et al., “Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease,” Alimentary Pharmacology and Therapeutics, vol. 21, no. 6, pp. 733–738, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Vesga, J. P. Terdiman, and U. Mahadevan, “Adalimumab use in pregnancy,” Gut, vol. 54, no. 6, article 890, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. D. S. Mishkin, W. Van Deinse, J. M. Becker, and F. A. Farraye, “Successful use of adalimumab (Humira) for Crohn's disease in pregnancy,” Inflammatory Bowel Diseases, vol. 12, no. 8, pp. 827–828, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. E. A. Vasiliauskas, J. A. Church, N. Silverman, M. Barry, S. R. Targan, and M. C. Dubinsky, “Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn,” Clinical Gastroenterology and Hepatology, vol. 4, no. 10, pp. 1255–1258, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Tursi, “Effect of intentional infliximab use throughout pregnancy in inducing and maintaining remission in Crohn's disease,” Digestive and Liver Disease, vol. 38, no. 6, pp. 439–440, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. E. Angelucci, A. Cocco, A. Viscido, and R. Caprilli, “Safe use of infliximab for the treatment of fistulizing Crohn's disease during pregnancy within 3 months of conception,” Inflammatory Bowel Diseases, vol. 14, no. 3, pp. 435–436, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Aratari, G. Margagnoni, M. Koch, and C. Papi, “Intentional infliximab use during pregnancy for severe steroid-refractory ulcerative colitis,” Journal of Crohn's and Colitis, vol. 5, no. 3, p. 262, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. R. M. Marchioni and G. R. Lichtenstein, “Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review,” World Journal of Gastroenterology, vol. 19, no. 17, pp. 2591–2602, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. N. Djokanovic, C. Klieger-Grossmann, A. Pupco, and G. Koren, “Safety of infliximab use during pregnancy,” Reproductive Toxicology, vol. 32, no. 1, pp. 93–97, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. U. Mahadevan, S. Cucchiara, J. S. Hyams et al., “The London position statement of the World Congress of gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics,” The American Journal of Gastroenterology, vol. 106, no. 2, pp. 214–223, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. A. de Lima, Z. Zelinkova, C. van der Ent, E. A. P. Steegers, and C. J. van der Woude, “Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety,” Gut, vol. 65, pp. 1261–1268, 2016. View at Publisher · View at Google Scholar · View at Scopus
  46. J. A. Katz, C. Antoni, G. F. Keenan, D. E. Smith, S. J. Jacobs, and G. R. Lichtenstein, “Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis,” The American Journal of Gastroenterology, vol. 99, no. 12, pp. 2385–2392, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. F. Schnitzler, H. Fidder, M. Ferrante et al., “Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy,” Inflammatory Bowel Diseases, vol. 17, no. 9, pp. 1846–1854, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. U. Mahadevan, C. F. Martin, R. S. Sandler et al., “865 PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy,” Gastroenterology, vol. 142, supplement 1, no. 5, p. S-149, 2012. View at Publisher · View at Google Scholar
  49. M. Bortlik, N. Machkova, D. Duricova et al., “Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study,” Scandinavian Journal of Gastroenterology, vol. 48, no. 8, pp. 951–958, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Z. Stengel and H. L. Arnold, “Is infliximab safe to use while breastfeeding?” World Journal of Gastroenterology, vol. 14, no. 19, pp. 3085–3087, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Ben-Horin, M. Yavzori, L. Katz et al., “Adalimumab level in breast milk of a nursing mother,” Clinical Gastroenterology and Hepatology, vol. 8, no. 5, pp. 475–476, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Ben-Horin, M. Yavzori, U. Kopylov et al., “Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease,” Journal of Crohn's and Colitis, vol. 5, no. 6, pp. 555–558, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. S. V. Kane, J. Ford, R. D. Cohen, and C. Wagner, “Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery,” Journal of Clinical Gastroenterology, vol. 43, no. 7, pp. 613–616, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Grosen, M. Julsgaard, J. Kelsen, and L. A. Christensen, “Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease,” Journal of Crohn's and Colitis, vol. 8, no. 2, pp. 175–176, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. G. C. Nguyen, C. H. Seow, C. Maxwell et al., “The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy,” Gastroenterology, vol. 150, no. 3, pp. 734–757.e1, 2016. View at Publisher · View at Google Scholar